EPCAM and hepatocellular carcinoma: A recent study conducted by Julich-Haertel et al. [60] with a large sample size (172 HCC or CCA patients) revealed that the abundance of AnnexinV+ EpCAM+ CD147+ tumor-associated microparticles (taMPs) was elevated in HCC and CCA, indicating that they are a novel biomarker of HCC and CCA.